The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approved for treatment for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients aged 2 months or older, accor…
There is a bidirectional association between rheumatoid arthritis (RA) and chronic obstructive pulmonary disease (COPD), according to a review published online Dec. 1 in Frontiers in Immunology.
Researchers at National Jewish Health and colleagues have completed the first study comparing lung macrophages in multiple models of lung injury. The research indicates that macrophages previously described as “pro-fibrotic” are insufficient to cause f…
Ever wondered why the color of your snot is different when you’re sick? You’re probably not the first person to ask this question.
Physician-researchers with City of Hope have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor (CAR) T cell therapy resistance. Their new system is outlined in a paper published in Nature Biomedica…
The human immune deficiency virus (HIV) first entered public consciousness in the early 1980s, after cases of unfamiliar and deadly illnesses began to overwhelm medical centers across North America.
Whenever a sink overflows, the flooding is usually caused by a blockage that has built up in the drains. Similarly, as we age, our bodies are flooded by aging, or senescent cells, which have stopped dividing but, instead of dying, remain active and bui…
In 2022 alone, over 20 million people were diagnosed with cancer, and nearly 10 million died from the disease, according to the World Health Organization. While the reaches of cancer are massive, the answer to more effective treatments may be hidden wi…
An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells and efficiently annihilating the malignancy without toxicity to the patient, a team of cancer biologists in France has found.
A new paper from MUSC Hollings Cancer Center researchers is helping to reveal the “rules” for engineering chimeric antigen receptor (CAR) Tregs.
